SCHEMBL482135

SCHEMBL482135

O=Cc1ccsc1B(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.39
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
ERN1 O75460 5/20 0.33
TRIM24 O15164 1/20 0.33
TRIM33 Q9UPN9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29517378 0.78 ERN1 (0.35) CYP2A6KDM4ETDP1ERN1TRIM24
SCHEMBL12419808 0.72 ALDH1A1 (0.58) KDM4EMEN1KMT2A
SCHEMBL21580184 0.71
SCHEMBL1419542 0.70 CYP2A6 (0.45) CYP2A6TDP1MEN1LMNATHRB
SCHEMBL225281 0.69
SCHEMBL2183638 0.69
SCHEMBL868397 0.69 MAPT (0.35)
SCHEMBL5435189 0.68 CYP2A6 (0.36) CYP2A6TDP1MEN1LMNATHRB
SCHEMBL14942555 0.67
SCHEMBL134580 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120118124-A Nitrogen-rich DOPO-based flame retardant, synthesis and application thereof 常州大学 2025-06-10 CN claimed
CN-113429381-B Bithiophene rotor derivative 3 '-acetyl- [2,2' -bithiophene ] -3-formaldehyde and preparation method and application thereof 山西大同大学 2023-03-21 CN claimed
CN-113429381-A Bithiophene rotor derivative 3 '-acetyl- [2,2' -bithiophene ] -3-formaldehyde, preparation method and application 山西大同大学 2021-09-24 CN claimed
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-20030119178-A1 DNA chip and its preparation SATO KOZO (JP) 2003-06-26 US claimed
US-6448238-B1 BORONIC ACIDS USED WITH BETA-LACTAM ANTIBIOTICS, SUCH AS AMOXICILLIN OR CEFTAZIDIME, TO TREAT BETA-LACTAM ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS NORTHWESTERN UNIVERSITY 2002-09-10 US claimed
US-6417174-B1 BACTERICIDES NORTHWESTERN UNIVERSITY 2002-07-09 US claimed
US-20010011129-A1 DNA chip and its preparation FUJI PHOTO FILM CO., LTD.; 2001-08-02 US claimed
EP-1009415-A4 INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR UNIV NORTHWESTERN (US) 2000-10-25 EP claimed
EP-1009415-A1 INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR NORTHWESTERN UNIVERSITY (US) 2000-06-21 EP claimed
US-6075014-A BACTERICIDES NORTHWESTERN UNIVERSITY (US) 2000-06-13 US claimed
WO-1998056392-A1 INHIBITORS OF β-LACTAMASES AND USES THEREFOR NORTHWESTERN UNIVERSITY (US) 1998-12-17 WO claimed
EP-4667458-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG Kanaph Therapeutics Inc. (KR) 2025-12-24 EP disclosed
CN-120118124-A Nitrogen-rich DOPO-based flame retardant, synthesis and application thereof 常州大学 2025-06-10 CN disclosed
WO-1999018099-A1 ARYL THIOPHENE DERIVATIVES AS PDE IV INHIBITORS MERCK FROSST CANADA & CO. (CA) 1999-04-15 WO disclosed
WO-1998056392-A1 INHIBITORS OF β-LACTAMASES AND USES THEREFOR NORTHWESTERN UNIVERSITY (US) 1998-12-17 WO disclosed
WO-1998016503-A2 THE PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1998-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010011129-A1 DNA chip and its preparation STUB1, DNMT3A, PCNA CYP2A6 2437/4885KDM4E 769/4885TDP1 117/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH CYP2A6 1752/4885KDM4E 1589/4885TDP1 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.